Pharma BD Deal Intelligence
Stryker's $5.4B acquisition of Wright Medical gave it a stronger foothold in extremities and biologics, rounding out its orthopedics portfolio beyond hips and knees. The deal closed at $30.75 per share, folding Wright Medical's extremities and biologics products directly into Stryker's device lineup.
Stryker acquired Wright Medical for $30.75 per share, representing total equity value of approximately $4 billion and enterprise value of approximately $5.4 billion including convertible notes. The deal strengthened Stryker's extremities and biologics portfolio.
Upper-extremity orthopedic implants segment by anatomy and device architecture, a pure medical-device competitive landscape. Reverse and anatomic total shoulder systems: Wright Medical's Aequalis Ascend Flex, Aequalis Perform Humeral System and Blueprint 3D planning software (legacy Tornier, now Stryker) compete against DePuy Synthes Delta XTEND Reverse, Zimmer Biomet Comprehensive Reverse Shoulder and Trabecular Metal Reverse, Arthrex Univers Revers, and Exactech Equinoxe Reverse Shoulder (the latter subject to a 2023 recall of polyethylene inserts affecting commercial trajectory). Elbow arthroplasty: Stryker/Wright's Nexel Total Elbow and Latitude EV compete with Zimmer Biomet Coonrad-Morrey (the long-standing share leader) and DJO/Enovis Discovery Elbow. Wrist, distal radius and hand fixation: Stryker/Wright's Micronail intramedullary distal radius system, VOLT, and Acumed Acu-Loc plating compete with Medartis Aptus, Zimmer Biomet DVR, and DePuy Synthes VA-LCP Two-Column. Commercial read: shoulder arthroplasty is the value driver (approximately $1.5B U.S. segment), with the combined Stryker + Wright platform achieving #1 position in shoulder, displacing Zimmer Biomet from the leadership role it held pre-2020. Wright Medical generated approximately $389M in upper-extremity sales in 2018 per its last standalone 10-K filing. Stryker's Mako robotics platform extension into shoulder (commercial launch 2023) is the durable competitive moat against Zimmer and Enovis.
Lower extremity (foot & ankle) orthopedic implants is a ~$4B global device market with a concentrated top-5 vendor base; Stryker's Wright Medical integration competes on implant category rather than pharmacologic MOA. Total ankle arthroplasty (TAA) implants: Stryker/Wright Medical INBONE/INFINITY and STAR (the category-leading portfolio post-acquisition); Zimmer Biomet Trabecular Metal Total Ankle; Smith & Nephew SALTO TALARIS; DePuy Synthes (J&J) AGILITY (legacy); Exactech Vantage Total Ankle. Foot & ankle fracture fixation (plates, screws, nails): DePuy Synthes (J&J MedTech, ~$14.7B FY2023 MedTech segment across all orthopedics); Stryker (~$5.2B Orthopedics segment FY2023); Zimmer Biomet (~$7.4B FY2023 global ortho); Smith & Nephew; Arthrex (private). Hallux/bunion correction systems: Stryker/Wright Prostep/Lapiplasty-adjacent; Treace Medical Concepts Lapiplasty (~$190M FY2023 pure-play); Paragon 28 (Zimmer-acquired 2025 pending); Nextremity. Biologics adjuncts: Stryker OrthoSonos, Tornier Augment bone graft. Robotics and navigation: Stryker Mako (extended to foot/ankle), Zimmer ROSA. For Stryker, the Wright acquisition elevated the franchise from a sub-scale player to category leader in TAA and complex reconstruction; the primary competitive threats are Treace (high-growth bunion), Paragon 28 (now Zimmer), and DePuy's broader hospital contracting leverage.
Augment Injectable (rhPDGF-BB + beta-TCP) enters a fragmented orthobiologics market segmented by three MOA classes. Recombinant growth factors: Medtronic's Infuse Bone Graft (rhBMP-2) is the entrenched market leader in spinal fusion, with Stryker's own Augment Bone Graft (rhPDGF-BB, FDA-approved 2015 for ankle/hindfoot fusion) now complemented by the injectable formulation targeting foot-and-ankle indications. Cellular allografts and demineralized bone matrix (DBM): Medtronic Grafton DBM, Zimmer Biomet CopiOs, and Orthofix Trinity Elite (viable cell allograft) dominate the volume segment. Synthetic ceramics and bioactive glass: Baxter (Synthes) Chronos, Stryker Vitoss (beta-TCP), and NovaBone putty serve price-sensitive accounts. Autograft harvest remains standard of care for complex fusions. Commercial read: Augment Injectable's rhPDGF-BB MOA is differentiated from rhBMP-2 on safety (no ectopic bone risk) but faces reimbursement headwinds; Stryker's integration with Wright's foot-and-ankle sales force is the core commercial lever. Orthobiologics segment generated approximately $2B in 2019 U.S. sales per Wright 10-K, with Augment contributing roughly $60M annually pre-acquisition.
Stryker to acquire Wright Medical for $30.75/share, ~$5.4B enterprise value. Part of Stryker Corporation's $5.4B deal to acquire Wright Medical Group N.V..
Stryker agreed to divest STAR total ankle replacement and total finger joint products to DJO Global, Inc. as an FTC consent-order condition; final FTC order Dec 11, 2020.
96% of shares tendered. Extremities portfolio integrated into Stryker trauma business.
See timeline for full assessment. Assessment of Stryker Corporation's $5.4B acquisition of Wright Medical Group N.V. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Stryker Corporation / Wright Medical Group N.V. (this deal) | 2019 | $5.4B | 81 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Stryker Corporation / Gaymar Industries | 2010 | $150M | 54 |
| Stryker Corporation / Trauson Holdings Company Limited | 2013 | $764M | 37 |
| Stryker Corporation / Inari Medical, Inc. | 2025 | $4.9B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
← Browse all deals · How we score deals
More: 2019 deals · Stryker Corporation deals